Best Grants for Cancer Nonprofits in Virgin Islands

Oncology Nursing Foundation

The mission of the Oncology Nursing Foundation is to support cancer nursing excellence.

Since 1981, the Oncology Nursing Foundation(ONF), through generous contributions from individuals and institutions, has provided more than $33 million in funding to support oncology nursing education, research and leadership development. This funding has translated to career development awards, academic scholarships, research grants, a myriad of specialized educational initiatives, as well as nurse resiliency support. The Foundation’s activities have played a critical role in improving patient care and advancing the oncology nursing profession.

Radiation Oncology Certified Nurse (ROCN™) Exam Scholarship

Recipients receive funding to cover the ONCC ROCN™ Certification exam fee.

Purpose

To support registered oncology nurses who specialize in providing care for adult or pediatric patients with cancer undergoing radiation therapy by providing funding support to cover the ROCN™ Certification exam fee. 

The National Mesothelioma Virtual Bank (NMVB) aims to enhance biomedical research on malignant mesothelioma by expanding its collection of biospecimens, including tumor tissues and blood samples, alongside demographic and clinical data. Established in 2006, the NMVB serves as a crucial resource for researchers, providing access to a diverse library of samples and data, which can help identify disease markers and develop improved treatment options. This initiative is essential for advancing the understanding and treatment of mesothelioma.

This initiative aims to support research interventions targeting disparities in liver diseases and liver cancer among underserved populations in the U.S. It encourages innovative approaches to reduce health inequities and improve health outcomes. The funding opportunity is available through various deadlines for both standard and renewal applications, promoting multi-level strategies to address these critical health issues effectively.

The National Cancer Institute (NCI) invites applications for the R33 grant aimed at advancing emerging technologies in cancer research. This funding opportunity seeks projects that demonstrate significant progress in technology development, focusing on cancer biology, early detection, and clinical diagnosis. Eligible proposals must showcase innovative methodologies that enhance research capabilities, with a strong emphasis on technical validation and broad applicability in cancer applications.

The Mission Boost Grants (MBG) by the American Cancer Society aim to enhance cancer research by funding projects that translate into human testing. These grants support investigators at all levels, offering resources for innovative clinical projects. The program consists of two funding stages: Stage I focuses on developing clear milestones for new treatments, while Stage II supports patient testing, ultimately contributing to advancements in cancer care and treatment.

The American Cancer Society's Mentored Research Grants for Postdoctoral Fellowships (PF) aim to support emerging researchers in their training programs, fostering their transition to independent cancer research careers. Eligible candidates include US citizens or non-citizens with valid visas who have completed their doctoral degrees within the last four years. The fellowship offers funding for up to three years, with stipends of $66,000 to $70,000 annually, alongside allowances for health insurance and professional development.

The Clinician Scientist Development Grant (CSDG) by the American Cancer Society supports full-time faculty aiming to become independent clinician scientists while maintaining clinical practice. Eligible applicants must hold a doctoral degree, an active clinical license, and have clinical care experience. The grant provides funding of $135,000 annually for 3 to 5 years, including allowable indirect costs, to advance cancer research in key priority areas.

The American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) co-fund the Clinician Scientist Development Grant (CSDG), aimed at advancing the research careers of clinician scientists in radiation oncology. Eligible applicants are full-time faculty members at U.S. institutions with a doctoral degree and an active clinical license. The grant supports research for 3 to 5 years, providing $135,000 annually for direct costs, plus allowable indirect costs, while encouraging diversity in applications.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

The National Cancer Institute (NCI) invites applications for innovative technologies aimed at cancer research and clinical care. This funding opportunity supports early-stage projects focused on proof-of-concept studies to assess the feasibility of new methods and tools. Applications should demonstrate significant technical innovation, targeting advancements in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology. Technologies may include novel analysis platforms, imaging technologies, and biospecimen processing innovations, with a focus on cancer applications.

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The National Cancer Institute (NCI) invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity allows for biphasic or monophasic applications to support both analytical and clinical validation phases. Successful projects will leverage human specimens to develop assays that enhance cancer treatment and prevention, ensuring multidisciplinary collaboration among scientists and clinicians. This initiative aims to improve cancer management through reliable and clinically validated tools.

This funding opportunity invites applications for R01 grants focused on molecular imaging methods to explore cancer inflammation in vivo. It aims to enhance understanding of dynamic interactions between inflammation and cancer through innovative imaging techniques. The initiative encourages collaborations between cancer researchers and imaging scientists to leverage molecular imaging for identifying cellular physiology changes in response to treatment. Deadline dates for applications range from February 2025 to October 2027, emphasizing timely submission for prospective researchers.

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers by funding comprehensive, clinical, and basic cancer research. These grants facilitate the integration of diverse research capabilities, promoting innovative approaches to cancer prevention, diagnosis, and therapy. CCSGs encourage collaboration among researchers and the development of Shared Resources, ultimately enhancing the understanding of cancer and its treatment. This initiative supports the continuous discovery and dissemination of crucial research findings for community benefit.

The National Cancer Institute's PAIRS program aims to explore innovative cancer therapies by leveraging synthetic vulnerabilities that interact with tumor responses to radiation therapy. This initiative supports the development of targeted drug-radiation combinations, focusing on precision medicine to optimize treatment efficacy while minimizing harm to normal tissues. By consolidating prior funding opportunities, PAIRS encourages research that addresses context-dependent vulnerabilities, enhancing therapeutic strategies and aligning with NIH's scientific goals.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The National Human Genome Research Institute (NHGRI) is launching a Notice of Funding Opportunity (NOFO) aimed at enhancing genomic research through the development and distribution of high-value resources. This initiative encourages collaborative efforts in genomic resource development and the integration of data science in clinical applications. While applications are not currently being accepted, prospective applicants are urged to prepare meaningful collaborations and projects ahead of the formal solicitation.

The NIH is inviting applications for interventions aimed at enhancing cancer screening and preventive services in underserved populations. This initiative focuses on addressing barriers to healthcare access and promoting timely follow-up on abnormal findings. Collaborations with community partners are encouraged to foster effective outreach. The program particularly seeks to engage patients, clinicians, and healthcare settings in improving health equity and outcomes in cancer prevention.

The National Cancer Institute (NCI) invites applications for studies on mechanisms by which bariatric surgery influences cancer risk. This funding opportunity encourages exploration beyond short-term outcomes like weight loss and diabetes. The goal is to support innovative proof of concept studies, emphasizing feasibility without prior development in the literature. Unpublished data is not allowed, but references from preprints with a DOI are acceptable. Deadlines for applications span from February 2025 to November 2027.